Witness Name: Daniel Patrick Eve
Statement No.: WITN7745001
Exhibits: None
Dated: 3 March 2024

INFECTED BLOOD INQUIRY

WRITTEN STATEMENT OF DANIEL PATRICK EVE

I provide this statement in response to a request under Rule 9(1) and (2) of the Inquiry Rules 2006 dated 8 February 2024.

I, Daniel Patrick Eve, will say as follows: -

1. I am the Head of Blood and Infection Programme of Care in the Specialised Commissioning department of NHS England.

2. My involvement in the matters to which the Inquiry relates is limited to the time that I began undertaking the role of Senior Manager of the Blood and Infection Programme of Care in Specialised Commissioning. This role commenced in November 2022. As a result of the NHS England reorganisation my job title changed to Head of Blood and Infection Programme from January 2024 although the role remains the same. The Blood and Infection Programme of Care incorporates the Blood Disorders Clinical Reference Group. This is the Group that advises NHS England on policy development in this clinical area.

3. In order to make a complete and accurate response to the Inquiry's request, it has been necessary for me to consult with Will Horsley, the Lead Commissioner for Blood Disorders and with the Specialised Commissioning Clinical Policy Team. In addition, the response has been reviewed and approved by John Steward, National Director, Specialised Commissioning and Matthew Day, Director of Clinical Commissioning, Specialised Commissioning.

Access to recombinant blood products for children with Von Willebrand Disease (VWD)

4. NHS England published a commissioning policy for vonicog alfa in March 2020 (which was updated in January 2021) entitled: *Clinical Commissioning Policy: Vonicog alfa for the treatment and prevention of bleeding in adults with von Willebrand disease*. This policy covers short-term episodic use of vonicog alfa (i.e. 'on- demand' to treat bleeding episodes and to prevent and treat bleeding during surgery). There are currently no recombinant von Willebrand factor products licenced for under 18s. A product license for vonicog alfa in patients under 18 years of age is not expected until 2026.

5. Nevertheless, NHS England commission and fund off-label usage of this treatment for eligible children under NHS England's commissioning medicines for children policy. This is essentially an extension of the adult policy to cover post-pubertal children.

6. In addition, NHS England also has a policy proposition under consideration for the same indication in patients aged under 12 years old. The approval to progress this proposal, and begin policy development, is pending a review of the available data and the evidence to support it.

7. NHS England are aware that there is an ongoing trial being run by Takeda. NHS England currently understands that the trial is due to close in 2025 with a peer reviewed publication of the results to follow. The results of this trial may be required to provide additional evidence for the policy development to be taken forward.

Statement of Truth

I believe that the facts stated in this witness statement are true.

Signed ____ GRO-C _____

Dated _____03/03/2024_____